简介：

简介：Theaimofthismanuscriptistoreviewtheactionandadverseeffectsofcombinedoralcontraceptives(COCs)onoculartissues.Thepercentageofunwantedpregnanciesandthesubsequentabortionsmakecontraceptioncrucialworldwide.Over100millionwomenaroundtheworldusecommoncontraceptivemethods,includingintrauterinedevices,combinedestrogenandprogestinoralcontraceptives,aswellasprogestinonlypreparations(oralcontraceptives,implantsorinjections).COCsarewidelyusedforcontraception,buttheyarealsoindicatedinmenorrhagia,endometriosis,acneandhirsutism,fibroiduterusandpremenstrualsyndrome.However,theyhavebeenassociatedwithhighratesofcardiovascularevents,venousthromboembolicdisease,ischemicstrokesandbreastcancer.TheincidenceofCOCs-relatedocularcomplicationsisestimatedtobe1in230000,includingdryeyesymptoms,cornealedema,lensopacitiesandretinalneuro-ophthalmologicorvascularcomplications.WemayinferthattheseriousocularcomplicationsofCOCscanbepreventedbyeliminatingtheestrogendosageandchoosingthird-generationprogestins.Inanycase,doctorsshouldtakeintoconsiderationthesystemicandocularhistoryofthepatientsbeforeselectinganymethodofcontraception.

简介：AIMTo把主要、周期性的pterygium外科的长期的结果与三种不同技术作比较：联合结膜自体移植和覆盖羊膜的膜移植(有AMT的猫)，结膜自体移植移植(猫)独自一个、羊膜的膜移植(AMT)alone.METHODSIn这回顾的研究，142个pterygium病人的142只眼睛(104主要，38周期性)经历了猫(组A)，AMT(组B)或有AMT(组C)的猫分别地后面的外科的切除基于复发和手术后的complications.RESULTSThe数字被考察并且比较一样的描述在下面)，18(10，8)并且2(1，1)在组A，B，和C分别地；干燥眼睛是22(16，6)，27(18，9)并且7(3，4)；结膜发炎是30(17，13)，27(16，11)并且11(6，5)。在组C(主要或周期性的任何一个或两个)的病人主要在组A或B比那些显示出显著地更好的结果(P<0.05)关于上述临床的effects.CONCLUSIONCombined猫并且过分AMT比猫或AMT为主要、周期性的pterygium外科有复发和手术后的复杂并发症的显著地更低的率独自一个。

简介：AIM:Toevaluatetheefficacyandsafetyofanti-vascularendothelialgrowthfactor(VEGF)combinedwithphotodynamictherapy(PDT)versusanti-VEGFmonotherapyforpolypoidalchoroidalvasculopathy(PCV).METHODS:WeconductedaMeta-analysisof9studiestocomparetheefficacyandsafetybetweencombinedtherapyandanti-VEGFmonotherapyforPCV.TheprogramsofRevMan5.3andStata12.0wereusedtoanalyzedata.RESULTS:Thebestcorrectedvisualacuity(BCVA)incombinedtherapygroupweresignificantlybetterthanthoseofanti-VEGFmonotherapygroupat6,24and36mo,withpooledweightedmeansdifferences(WMDs)of0.12(0.06,0.18),0.25(0.12,0.38)and0.28(0.13,0.43),respectively.Thecentralretinalthickness(CRT)reductionsincombinedtherapygroupwerehigherthanthatinantiVEGFmonotherapygroupat1,3,6and9mo,withpooledWMDsof63.90(20.41,107.38),33.47(4.69,62.24),30.57(0.12,60.01)and28.00(2.51,53.49),respectively.Theregressionrateofpolypsincombinedtherapygroupwasmuchhigherthanthatinanti-VEGFmonotherapygroup[RD:0.47(0.26,0.68);P<0.0001].Theadverseeventretinalhemorrhagedidnotdiffersignificantlybetweenthetwogroups.CONCLUSION:OurfindingsclearlydocumentthatantiVEGFcombinedwithPDTisamoreeffectivetherapyforPCVcomparedwithanti-VEGFmonotherapy.Furthermore,combinedtherapydoesnotincreasetheincidenceofretinalhemorrhage.

简介：AIM:Toevaluatetheefficacyandsafetyofacombinedtreatmentformyopicchoroidalneovascularization(CNV)usingphotodynamictherapy(PDT)andintravitrealbevacizumabandtocompareitwithintravitrealbevacizumabmonotherapy.METHODS:Thirty-foureyeswithangiographicevidenceofmyopicCNVwererandomlydividedintotwogroups:17weretreatedwithoneintravitrealbevacizumabinjection(1.25mg)andlow-fluence-ratePDTwithinsevendaysoftheinjection(GroupA).Theother17receivedmonotherapywithbevacizumabinjections(GroupB).Clinicalevidenceofcomplications,bestcorrectedvisualacuity(BCVA)andfluoresceinleakagewereevaluated.BCVAandopticalcoherencetomography(OCT)wereevaluatedmonthly.Thetimepointsfollow-upwasestablishedat6and12mo.AllpatientswereretreatedfollowingaPRNprotocol.RESULTS:Atotalof34eyesof34patients(26womenand8men)withameanageof62.35yearswereincluded.InGroupA(17eyes)themeanBCVAincreasedfrom0.55±0.13logMARbeforethetreatmentto0.40±0.09logMARatthe12mofollow-up(P<0.01).InGroupB(17eyes)themeanBCVAincreasedfrom0.60±0.11logMARbeforethetreatmentto0.55±0.12logMARatthe12mofollow-up(P<0.01).TherewasnostatisticallysignificantdifferencebetweenthetwogroupsintermsofLogMarvisualacuity.InGroupAthemeannumberofcombinedtreatmentswas1.8±0.11perpatient;inGroupBthemeannumberofintravitrealbevacizumabinjectionswas3.1±0.08perpatient.ThenumberoftreatmentswassignificantlyfewerinGroupA(P<0.01).Nolocalorsystemicsideeffectsoccurredamonganyofthepatientstreatedinthisstudy.CONCLUSION:Thecombinationofanti-angiogenicinjectionsandPDTappearstobeasafeandeffectiveoptionformyopicCNVtreatmentandallowsforasignificantreductionofintravitrealinjections.

简介：AIMTo比较fluorometholone的联合0.1%并且0.5%在控制发炎并且与intraocular透镜implantation.METHODSSixty在phacoemulsification以后阻止感染掉到tobramycin/dexamethasone眼睛的levofloxacin从60看经历奔流phacoemulsification的病人被使随机化进二个组；病人的一半与与levofloxacin(4times/d)相结合的fluorometholone(6times/d)被对待，当另外的一半与眼睛掉一个星期的tobramycin/dexamethasone(4times/d)被对待时。在操作和1wk追随者treatments.RESULTSThere不是在角膜的厚度(P0.629)的二个组之间的统计上重要的差别以前，外科手术前、手术后的intraocular压力，水的闪光，角膜的厚度，和症状被记录，水的闪光(P0.398)，并且症状分数(P0.350)在每次指。眼睛的高血压仅仅在与levofloxacin治疗表演相结合的tobramycin/dexamethasonegroup.CONCLUSIONFluorometholone在二只眼睛被观察可比较的功效但是没有增加intraocular压力的趋势；因此，它可能是为手术后的使用的更好的政体。